Ezetimibe is most likely to cause urticaria among these three medications.
Based on FDA drug labeling, ezetimibe explicitly lists urticaria as a documented hypersensitivity reaction in both its contraindications and post-marketing adverse events 1. The FDA label specifically states that ezetimibe is contraindicated in patients with known hypersensitivity, with urticaria being one of the identified hypersensitivity reactions reported during post-approval use 1.
Evidence-Based Ranking by Urticaria Risk:
1. Ezetimibe (Highest Risk)
- Documented urticaria in FDA labeling as a hypersensitivity reaction 1
- Listed under "Immune System Disorders" in post-marketing surveillance
- Part of a spectrum including anaphylaxis, angioedema, rash, and urticaria
- A 2023 case report documented urticaria and pruritus as a negative outcome related to Rosuvastatin/Ezetimibe combination, which resolved upon discontinuation 2
2. Valsartan (Moderate Risk)
- A 2026 case report documented the first immediate urticarial reaction to valsartan in the literature 3
- Patient developed urticarial rash 30 minutes after cumulative dose of 160 mg
- ARBs as a class can potentially induce angioedema and urticaria 4
- However, this remains rare with limited published cases
3. Atorvastatin (Lowest Risk)
- No specific urticaria documentation in the provided evidence
- When combined with ezetimibe, adverse events were similar to statin monotherapy 1
- The case of urticaria attributed to Rosuvastatin/Ezetimibe combination 2 more likely reflects ezetimibe's contribution given its established urticaria profile
Clinical Approach to Suspected Drug-Induced Urticaria:
If urticaria develops in this patient:
- Temporal relationship assessment: Document when urticaria started relative to each medication initiation
- Discontinuation trial: Stop ezetimibe first given its documented urticaria profile
- Monitor for resolution: Urticaria should improve within days to weeks if drug-related
- Consider alternatives:
Important Caveats:
- Drug combinations complicate attribution: The patient taking both ezetimibe and atorvastatin makes individual drug causality challenging 2
- Delayed vs immediate reactions: Ezetimibe typically causes hypersensitivity reactions (timing unspecified in labeling), while the valsartan case showed immediate reaction after 1 year of use 3
- Patch testing limitations: The valsartan case showed negative patch tests despite positive oral challenge, indicating skin testing may not predict urticarial reactions 3
The evidence clearly prioritizes ezetimibe as the most likely culprit based on established FDA documentation, with valsartan as a distant second possibility, and atorvastatin as the least likely cause.